Equity Details
Price & Market Data
Price: $3.89
Daily Change: $0.00 / 0.00%
Daily Range: $3.89 - $4.00
Market Cap: $1,648,294,893
Daily Volume: 1,800
Performance Metrics
1 Week: 0.78%
1 Month: 0.78%
3 Months: -16.65%
6 Months: -30.54%
1 Year: 21.56%
YTD: -16.65%
About CanSino Biologics Inc. (CASBF)
Understand CanSino Biologics Inc. (CASBF)'s market. Price: 3.89, daily change: $0.00 / 0.00%. Market cap: 1,648,294,893. Performance 1-month, 6-month, 52-week.
Company Details
Employees: 1134
Sector: Health technology
Industry: Biotechnology
Country: China
Details
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
